J Korean Ophthalmol Soc > Volume 54(7); 2013 > Article
Journal of the Korean Ophthalmological Society 2013;54(7):1130-1134.
DOI: https://doi.org/10.3341/jkos.2013.54.7.1130    Published online July 15, 2013.
Macular Hole after Single Intravitreal Injection of Ranibizumab in a Patient with Age-Related Macular Degeneration.
Jong Min Kim, Jun Won Jang, Sung Eun Kyung, Moo Hwan Chang
Department of Ophthalmology, Dankook University Medical College, Cheonan, Korea. changmh@dankook.ac.kr
신생혈관성 나이관련황반변성 환자에서 1차 루센티스 안내주사 후 발생한 전층황반원공 1예
김종민⋅장준원⋅경성은⋅장무환
Department of Ophthalmology, Dankook University Medical College, Cheonan, Korea
Abstract
PURPOSE
To report a case of a full-thickness macular hole after a single intravitreal injection of ranibizumab in a patient with choroidal neovascularization associated with age-related macular degeneration. CASE SUMMARY: A 63-year-old woman presented to our department with gradually decreasing vision in her right eye. Best corrected visual acuity (BCVA) was measured as 0.7 in the right eye and 1.0 in the left eye. Examination of the macula showed a choroidal neovascularization associated with subretinal hemorrhage in the right eye. Optical coherence tomography (OCT) confirmed incomplete posterior vitreous detachment, subretinal hemorrhage and serous elevation. The patient subsequently received an intravitreal ranibizumab injection. After 1 month, the best corrected visual acuity in the right eye was decreased to 0.4, and fundus examination revealed posterior vitreous detachment and a macular hole. The patient underwent pars plana vitrectomy with internal limiting membrane peeling and fluid-air exchange, SF6 gas injection, phacoemulsification and posterior chamber intraocular lens implantation. Three months later, the macular hole had closed completely and best visual acuity was 1.0. CONCLUSIONS: Although the occurrence of a full-thickness macular hole after intravitreal ranibizumab injection is uncommon, physicians should be well acquainted with this complication.
Key Words: Intravitreal;Lucentis;Macular hole;Ranibizumab


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next